1. Home
  2. Advocacy
  3. Laboratory Oversight and Regulation
  4. Federal Public Health Information and Advocacy

Federal Public Health Information and Advocacy

Federal agencies regularly issue guidance and regulations concerning the COVID-19 pandemic and related health care issues. The CAP engages with the federal government and Congress on related public health policies through its mission of serving patients and the public by advocating excellence in the practice of pathology and laboratory medicine. Review and click on the latest information below from the Centers for Disease Control and Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), and other regulatory bodies. Many state, city, and other local municipalities may have additional guidance for the public to follow in their own communities.

Testing Guidance

Updated January 21, 2022: The CDC recommends people who have symptoms of COVID-19 or who have had known close contact to someone with COVID-19 should be tested.

Go to the CDC’s website for information on testing strategies for SARS-CoV-2, antibody testing guidelines, pooling testing, and more.

Vaccine Guidance

Updated June 17, 2022: The FDA expanded eligibility for the Pfizer-BioNTech and Moderna vaccines for children down to six months of age. Previously, the FDA amended emergency use authorizations for Moderna and Pfizer-BioNTech vaccines by authorizing use of booster doses. Additional guidance for the Janssen (Johnson & Johnson), Spikevax, and Comirnaty vaccines are also available from the FDA.

Public Health Recommendations

Updated June 24, 2022: The CDC recommends that individuals get vaccinated and stay up to date. Additional guidance is provided for people who are moderately or severely immunocompromised.

CAP Statements and Letters